Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Autonomous University of Barcelona , Barcelona, Spain.
Expert Opin Pharmacother. 2020 Jun;21(9):1005-1013. doi: 10.1080/14656566.2020.1739269. Epub 2020 Mar 26.
Ceftolozane-tazobactam is a combination of a new cephalosporin, with activity similar to that of ceftazidime, and a known inhibitor of beta-lactamases. This compound shows excellent activity against most gram-negative organisms causative of hospital-acquired pneumonia (HAP) or ventilator-acquired pneumonia (VAP), including extended spectrum beta-lactamase (ESBL)-producing Enterobacterales and multidrug-resistant (MDR) .
This article reviews the spectrum of activity, the main pharmacokinetic and pharmacodynamic characteristics and the clinical efficacy and safety of ceftolozane-tazobactam in the treatment of HAP/VAP in adult patients.
The results of a randomized clinical trial have demonstrated an efficacy and safety profile of ceftolozane-tazobactam similar to that of its comparator for the treatment of patients with HAP/VAP. Several retrospective studies have shown good efficacy of the drug for the treatment of respiratory infections caused by MDR . The use of this drug may be incorporated as a new therapeutic option for the treatment of patients with HAP/VAP in a carbapenem-saving setting or as a therapeutic alternative with a better safety profile than other therapeutic options in patients with infections caused by MDR .
头孢他洛酯-他唑巴坦是一种新型头孢菌素与β-内酰胺酶抑制剂的复方制剂，其活性类似于头孢他啶。该化合物对大多数引起医院获得性肺炎（HAP）或呼吸机相关性肺炎（VAP）的革兰氏阴性病原体具有出色的活性，包括产超广谱β-内酰胺酶（ESBL）的肠杆菌科和多药耐药（MDR）。
本文综述了头孢他洛酯-他唑巴坦在治疗成人 HAP/VAP 中的活性范围、主要药代动力学和药效学特征以及临床疗效和安全性。
一项随机临床试验的结果表明，头孢他洛酯-他唑巴坦的疗效和安全性与对照药物相当，可用于治疗 HAP/VAP 患者。几项回顾性研究表明，该药物对治疗 MDR 引起的呼吸道感染具有良好的疗效。在碳青霉烯类药物节约治疗环境下，或在治疗 MDR 感染患者时，其安全性优于其他治疗选择时，该药物可作为一种新的治疗选择纳入治疗 HAP/VAP 患者。
